BioArctic
Biopharmaceutical firm developing antibody therapies for neurodegenerative diseases.
BIOA | ST
Overview
Corporate Details
- ISIN(s):
- SE0010323303 (+1 more)
- LEI:
- 549300Y0OI2WVUNHLC33
- Country:
- Sweden
- Address:
- Warfvinges väg 35, 112 51 Stockholm
- Website:
- https://www.bioarctic.se/en/
Description
BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-28 18:30 |
Number of shares and votes in BioArctic AB (publ) as of November 28, 2025
|
English | 186.5 KB | ||
| 2025-11-28 18:30 |
Antal aktier och röster i BioArctic AB (publ) per den 28 november 2025
|
Swedish | 205.9 KB | ||
| 2025-11-28 06:30 |
Ansökan om marknadsgodkännande för subkutan behandling med Leqembi[®] inlämnad …
|
Swedish | 222.5 KB | ||
| 2025-11-28 06:30 |
New drug application for subcutaneous formulation of Leqembi[®] submitted in Ja…
|
English | 201.6 KB | ||
| 2025-11-25 13:37 |
Eisai slutför stegvis ansökan för subkutan initieringsbehandling med Leqembi® I…
|
Swedish | 220.9 KB | ||
| 2025-11-25 13:37 |
Eisai completes U.S. rolling sBLA submission for Leqembi® Iqlik™ (lecanemab-irm…
|
English | 206.5 KB | ||
| 2025-11-13 08:00 | Swedish | 1.8 MB | |||
| 2025-11-13 08:00 | English | 1.7 MB | |||
| 2025-10-30 11:00 |
Försäljningen av Leqembi® uppgick till 18 miljarder yen under det tredje kvarta…
|
Swedish | 216.8 KB | ||
| 2025-10-30 11:00 |
Sales of Leqembi® totaled 18 billion yen in the third quarter 2025
|
English | 198.1 KB | ||
| 2025-10-17 15:00 |
BioArctic presents Nomination Committee
|
English | 226.6 KB | ||
| 2025-10-17 15:00 |
BioArctic presenterar valberedningen
|
Swedish | 225.6 KB | ||
| 2025-09-29 08:15 |
Kina godkänner intravenös underhållsbehandling med Leqembi®
|
Swedish | 235.6 KB | ||
| 2025-09-29 08:15 |
Leqembi® approved for IV maintenance treatment in China
|
English | 229.9 KB | ||
| 2025-09-24 08:40 |
Leqembi® approved for the treatment of early Alzheimer’s disease in Australia
|
English | 237.4 KB |
Automate Your Workflow. Get a real-time feed of all BioArctic filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioArctic
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioArctic via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-13 | Gunilla Osswald | Other | Sell | 40,000 | 8,821,200.00 SEK |
| 2025-02-13 | Gunilla Osswald | Other | Other | 40,000 | 3,344,000.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Sell | 6,000 | 1,323,180.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Other | 6,000 | 501,600.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Sell | 1,500 | 330,795.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 2,500 | 209,000.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 1,500 | 125,400.00 SEK |
| 2025-01-10 | Mikael Smedeby | Other | Buy | 730 | 148,920.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 2,000 | 446,000.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 871 | 195,626.60 SEK |
Peer Companies
